Compare PRLB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRLB | TRVI |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2011 | 2019 |
| Metric | PRLB | TRVI |
|---|---|---|
| Price | $72.88 | $13.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $53.00 | $21.55 |
| AVG Volume (30 Days) | 164.1K | ★ 1.1M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | 31.91 |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $6.89 | N/A |
| P/E Ratio | $226.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.40 | $5.41 |
| 52 Week High | $78.52 | $16.12 |
| Indicator | PRLB | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 43.10 |
| Support Level | $47.24 | $13.12 |
| Resistance Level | $73.11 | $13.55 |
| Average True Range (ATR) | 2.43 | 0.57 |
| MACD | -0.26 | -0.12 |
| Stochastic Oscillator | 41.93 | 15.34 |
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.